REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19
- PMID: 32610110
- PMCID: PMC7322471
- DOI: 10.1016/j.jinf.2020.06.063
REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19
Keywords: Biologic drugs; COVID-19; IL-17; Pulmonary fibrosis; SARS-CoV-2.
Conflict of interest statement
Declaration of Competing Interest The authors declare no competing interests
Comment on
-
Interleukin-17: A potential therapeutic target in COVID-19.J Infect. 2020 Aug;81(2):e136-e138. doi: 10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3. J Infect. 2020. PMID: 32504739 Free PMC article. No abstract available.
References
-
- Chinese Clinical Trial Register [Internet]. Changsha (Hu'nan): Ministry of Health (China). 2020 Mar 10 - . Identifier ChiCTR2000030703, A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19).
-
- Lionetti V., Recchia F.A., Ranieri V.M. Overview of ventilator-induced lung injury mechanisms. Curr Opin Crit Care. 2005;11:82–86. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous